Last reviewed · How we verify

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam

Hannover Medical School · Phase 3 active Small molecule

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam is a Broad-spectrum antibiotic combination Small molecule drug developed by Hannover Medical School. It is currently in Phase 3 development for Intra-abdominal infections with mixed aerobic and anaerobic flora, Complicated appendicitis or peritonitis.

This is a combination antibiotic regimen that uses fluoroquinolone and nitroimidazole agents (or beta-lactam with beta-lactamase inhibitor) to provide broad-spectrum coverage against aerobic and anaerobic bacteria.

This is a combination antibiotic regimen that uses fluoroquinolone and nitroimidazole agents (or beta-lactam with beta-lactamase inhibitor) to provide broad-spectrum coverage against aerobic and anaerobic bacteria. Used for Intra-abdominal infections with mixed aerobic and anaerobic flora, Complicated appendicitis or peritonitis.

At a glance

Generic nameMoxifloxacin/Metronidazole or Piperacillin/Tazobactam
SponsorHannover Medical School
Drug classBroad-spectrum antibiotic combination
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Moxifloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, while metronidazole is a nitroimidazole that generates reactive intermediates to damage anaerobic bacterial DNA. Alternatively, piperacillin/tazobactam combines a broad-spectrum penicillin with a beta-lactamase inhibitor to overcome resistance mechanisms. Together, these combinations provide synergistic coverage of gram-positive, gram-negative, and anaerobic pathogens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Moxifloxacin/Metronidazole or Piperacillin/Tazobactam

What is Moxifloxacin/Metronidazole or Piperacillin/Tazobactam?

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam is a Broad-spectrum antibiotic combination drug developed by Hannover Medical School, indicated for Intra-abdominal infections with mixed aerobic and anaerobic flora, Complicated appendicitis or peritonitis.

How does Moxifloxacin/Metronidazole or Piperacillin/Tazobactam work?

This is a combination antibiotic regimen that uses fluoroquinolone and nitroimidazole agents (or beta-lactam with beta-lactamase inhibitor) to provide broad-spectrum coverage against aerobic and anaerobic bacteria.

What is Moxifloxacin/Metronidazole or Piperacillin/Tazobactam used for?

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam is indicated for Intra-abdominal infections with mixed aerobic and anaerobic flora, Complicated appendicitis or peritonitis.

Who makes Moxifloxacin/Metronidazole or Piperacillin/Tazobactam?

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam is developed by Hannover Medical School (see full Hannover Medical School pipeline at /company/hannover-medical-school).

What drug class is Moxifloxacin/Metronidazole or Piperacillin/Tazobactam in?

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam belongs to the Broad-spectrum antibiotic combination class. See all Broad-spectrum antibiotic combination drugs at /class/broad-spectrum-antibiotic-combination.

What development phase is Moxifloxacin/Metronidazole or Piperacillin/Tazobactam in?

Moxifloxacin/Metronidazole or Piperacillin/Tazobactam is in Phase 3.

What are the side effects of Moxifloxacin/Metronidazole or Piperacillin/Tazobactam?

Common side effects of Moxifloxacin/Metronidazole or Piperacillin/Tazobactam include Diarrhea, Nausea, Abdominal pain, Metallic taste (metronidazole), Tendinopathy (fluoroquinolone), Photosensitivity (fluoroquinolone).

Related